Trovagene Inc (TROV) 4.85 $TROV
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TrovaGene (TROV) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 10:47AM CDT
TrovaGene (TROV) Enters Oversold Territory
Clinical Data Presented at AACR Demonstrate Ability of Trovagene's Molecular Diagnostic Platform to Non-Invasively Track Cancer Patients' Response to Therapy
PR Newswire - Tue Apr 08, 10:00AM CDT
Clinical study results presented today at the American Association for Cancer Research (AACR) Annual Meeting demonstrate the ability of Trovagene's (NASDAQ: TROV) molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients. The results were presented by Filip Janku, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center.
Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting
PR Newswire - Tue Apr 01, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.
Trovagene names Dr Charles Cantor to SAB
M2 - Thu Mar 27, 6:10AM CDT
Molecular diagnostics company Trovagene (NASDAQ:TROV) disclosed on Wednesday that Charles Cantor PhD, has been elected to its Scientific Advisory Board (SAB).
Genomics and Molecular Diagnostics Pioneer Charles Cantor, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Mar 26, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Charles Cantor, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer reviewed articles, authored and co-authored more than 50 U.S. and international patents, and is also an author of the first genomics textbook, Genomics: The Science and Technology of the Human Genome Project.
Trovagene and Catholic Health Initiatives Center for Translational Research Partner to Clinically Evaluate Non-Invasive Genomic Diagnostics to Improve Cancer Care
PR Newswire - Wed Mar 19, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV) and Catholic Health Initiatives Center for Translational Research (CTR) today announced they have entered into a strategic partnership to conduct clinical validation studies, clinical utility studies, health economic studies, and other activities to determine the effectiveness of Trovagene's urine-based cell-free DNA cancer monitoring diagnostics in clinical practice. CTR is a limited liability company whose sole corporate member is Catholic Health Initiatives Institute for Research and Innovation (CIRI), a direct subsidiary of Catholic Health Initiatives (CHI). Englewood Colorado-based CHI is one of the nation's largest health systems, operating in 18 states and comprising 87 hospitals, including four academic medical centers and teaching hospitals and 24 critical-access facilities.
Trovagene, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 17, 3:00PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.
Trovagene Releases Its First Oncogene Mutation Assay Using Next Generation Sequencing, Expands Its Non-Invasive Cancer Monitoring Platform
PR Newswire - Mon Mar 17, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has released its first multiplexed oncogene mutation assay, integrating the Company's proprietary sample preparation and primer technologies with next-generation sequencing (NGS) as a mutation detection platform.
Trovagene Schedules Release of Fourth Quarter and Year End 2013 Financial Results and Investor Conference Call
PR Newswire - Mon Mar 03, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
3 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 28, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Dr. Rodney S. Markin Joins Trovagene's Board of Directors
PR Newswire - Wed Feb 19, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Rodney S. Markin has joined the Company's Board of Directors. Dr. Markin is a hepatic pathologist by training, and is a leading authority in the field of laboratory automation.
Trovagene to Present at Two Upcoming Investor Conferences
PR Newswire - Thu Feb 06, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2014 healthcare and investor conferences next week in New York: BIO CEO & Investor Conference and Leerink Global Healthcare Conference.
Trovagene and US Oncology Research Collaborate on a Prospective Study for Urine-based KRAS Testing in Patients with Metastatic Pancreatic Cancer
PR Newswire - Mon Jan 06, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, and US Oncology Research, one of the largest community-based research programs in the United States, announced today that they have entered into a Clinical Study Agreement to examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients. US Oncology Research draws from a network of experienced investigators and clinical staff who specialize in Phase I through Phase IV oncology clinical trials. In addition to the 11 US Oncology Research affiliated community cancer care sites participating in this study, academic research institutions that specialize in oncology have also elected to participate.
Trovagene to Present at 25th Annual Piper Jaffray Conference
PR Newswire - Mon Dec 02, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the Piper Jaffray 25th Annual Healthcare Conference.
Empire Asset Management terminates coverage on TrovaGene (NASDAQ:TROV).
PR Newswire - Fri Nov 22, 10:07AM CST
Effective today Empire Asset Management Company, a FINRA member (143007) terminated coverage of TrovaGene (NASDAQ:TROV). We are discontinuing coverage of TrovaGene Inc because the analyst covering the company is no longer associated with the firm. Shares of TrovaGene have been rated a buy since May 6, 2013. Investors should no longer rely on Empire Asset Management research for an investment recommendation on TrovaGene.
Global Cancer Diagnostic Testing Market Report 2013
M2 - Fri Nov 15, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/fp8dbc/cancer_diagnostic) has announced the addition of the "Global Cancer Diagnostic Testing Market Report 2013" report to their offering. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Abbott Diagnostics - Bard Diagnostics, Inc. - Byk Gulden - Cepheid - DRG International, Inc. - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Geron Corporation - Hologic, Inc. (formerly Cytyc Corporation) - Immunicon Corporation (now Veridex, LLC) - Immunomedics, Inc. - LabCorp - Myriad Genetics, Inc. - Nexell Therapeutics, Inc. - Oncotech, Inc. - Polymedco, Inc. - Princeton BioMeditech Corporation - Qiagen - Roche (F. Hoffman-La Roche, Ltd.) - Sanko Junyaku Co., Ltd. - Siemens Heathcare Diagnostics - Tosoh Corporation (Bioscience division) - Ventana Medical Systems, Inc. - Veridex, LLC - Vermillion, Inc. - Worldwide Medical Corporation - Xenomics, Inc. (TrovaGene, Inc.) For more information visit http://www.researchandmarkets.com/research/fp...diagnostic
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TrovaGene (TROV) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 10:47AM CDT
TrovaGene (TROV) Enters Oversold Territory
Clinical Data Presented at AACR Demonstrate Ability of Trovagene's Molecular Diagnostic Platform to Non-Invasively Track Cancer Patients' Response to Therapy
PR Newswire - Tue Apr 08, 10:00AM CDT
Clinical study results presented today at the American Association for Cancer Research (AACR) Annual Meeting demonstrate the ability of Trovagene's (NASDAQ: TROV) molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients. The results were presented by Filip Janku, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center.
Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting
PR Newswire - Tue Apr 01, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.
Trovagene names Dr Charles Cantor to SAB
M2 - Thu Mar 27, 6:10AM CDT
Molecular diagnostics company Trovagene (NASDAQ:TROV) disclosed on Wednesday that Charles Cantor PhD, has been elected to its Scientific Advisory Board (SAB).
Genomics and Molecular Diagnostics Pioneer Charles Cantor, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Mar 26, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Charles Cantor, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer reviewed articles, authored and co-authored more than 50 U.S. and international patents, and is also an author of the first genomics textbook, Genomics: The Science and Technology of the Human Genome Project.
Trovagene and Catholic Health Initiatives Center for Translational Research Partner to Clinically Evaluate Non-Invasive Genomic Diagnostics to Improve Cancer Care
PR Newswire - Wed Mar 19, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV) and Catholic Health Initiatives Center for Translational Research (CTR) today announced they have entered into a strategic partnership to conduct clinical validation studies, clinical utility studies, health economic studies, and other activities to determine the effectiveness of Trovagene's urine-based cell-free DNA cancer monitoring diagnostics in clinical practice. CTR is a limited liability company whose sole corporate member is Catholic Health Initiatives Institute for Research and Innovation (CIRI), a direct subsidiary of Catholic Health Initiatives (CHI). Englewood Colorado-based CHI is one of the nation's largest health systems, operating in 18 states and comprising 87 hospitals, including four academic medical centers and teaching hospitals and 24 critical-access facilities.
Trovagene, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 17, 3:00PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.
Trovagene Releases Its First Oncogene Mutation Assay Using Next Generation Sequencing, Expands Its Non-Invasive Cancer Monitoring Platform
PR Newswire - Mon Mar 17, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has released its first multiplexed oncogene mutation assay, integrating the Company's proprietary sample preparation and primer technologies with next-generation sequencing (NGS) as a mutation detection platform.
Trovagene Schedules Release of Fourth Quarter and Year End 2013 Financial Results and Investor Conference Call
PR Newswire - Mon Mar 03, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
3 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 28, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Dr. Rodney S. Markin Joins Trovagene's Board of Directors
PR Newswire - Wed Feb 19, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Rodney S. Markin has joined the Company's Board of Directors. Dr. Markin is a hepatic pathologist by training, and is a leading authority in the field of laboratory automation.
Trovagene to Present at Two Upcoming Investor Conferences
PR Newswire - Thu Feb 06, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2014 healthcare and investor conferences next week in New York: BIO CEO & Investor Conference and Leerink Global Healthcare Conference.
Trovagene and US Oncology Research Collaborate on a Prospective Study for Urine-based KRAS Testing in Patients with Metastatic Pancreatic Cancer
PR Newswire - Mon Jan 06, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, and US Oncology Research, one of the largest community-based research programs in the United States, announced today that they have entered into a Clinical Study Agreement to examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients. US Oncology Research draws from a network of experienced investigators and clinical staff who specialize in Phase I through Phase IV oncology clinical trials. In addition to the 11 US Oncology Research affiliated community cancer care sites participating in this study, academic research institutions that specialize in oncology have also elected to participate.
Trovagene to Present at 25th Annual Piper Jaffray Conference
PR Newswire - Mon Dec 02, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the Piper Jaffray 25th Annual Healthcare Conference.
Empire Asset Management terminates coverage on TrovaGene (NASDAQ:TROV).
PR Newswire - Fri Nov 22, 10:07AM CST
Effective today Empire Asset Management Company, a FINRA member (143007) terminated coverage of TrovaGene (NASDAQ:TROV). We are discontinuing coverage of TrovaGene Inc because the analyst covering the company is no longer associated with the firm. Shares of TrovaGene have been rated a buy since May 6, 2013. Investors should no longer rely on Empire Asset Management research for an investment recommendation on TrovaGene.
Global Cancer Diagnostic Testing Market Report 2013
M2 - Fri Nov 15, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/fp8dbc/cancer_diagnostic) has announced the addition of the "Global Cancer Diagnostic Testing Market Report 2013" report to their offering. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Abbott Diagnostics - Bard Diagnostics, Inc. - Byk Gulden - Cepheid - DRG International, Inc. - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Geron Corporation - Hologic, Inc. (formerly Cytyc Corporation) - Immunicon Corporation (now Veridex, LLC) - Immunomedics, Inc. - LabCorp - Myriad Genetics, Inc. - Nexell Therapeutics, Inc. - Oncotech, Inc. - Polymedco, Inc. - Princeton BioMeditech Corporation - Qiagen - Roche (F. Hoffman-La Roche, Ltd.) - Sanko Junyaku Co., Ltd. - Siemens Heathcare Diagnostics - Tosoh Corporation (Bioscience division) - Ventana Medical Systems, Inc. - Veridex, LLC - Vermillion, Inc. - Worldwide Medical Corporation - Xenomics, Inc. (TrovaGene, Inc.) For more information visit http://www.researchandmarkets.com/research/fp...diagnostic
